Laurus Labs Ltd

Stage 2 · Advancing · week 25Setup 7.0 ★★ GoodStrong +6.5

As of 9 Oct 2026, Laurus Labs is in Stage 2 — advancing, the uptrend phase, in week 25 (since 21 Apr 2026). It closed at ₹2,037, 0.8% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. More about the company

₹2,036.6
+1.94% today
₹1.10L Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

7.0 ★★ Good

Momentum

Steady

Edge

Strong +6.5

Setup-score rank among Stage 2 peers: #10 of 61 in Pharmaceuticals · #10 of 78 in Health Care

Is LAURUSLABS early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-0.8%
₹853.1 lo₹2,052.8 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 25
1w13w26w
Week 25 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
47.7%
200 DMA: ₹1,379.2 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.55x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +2.8% vs MA50 +9.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+4.6%
3M
+32.4%
6M
+88.1%
YTD
+90.6%
1Y
+133.7%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #6 of 74 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #6 of 58 Stage 2 stocks in this industry. Top tier.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 46w
S2 50w
S2 25w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 4w → S2 13w → S3 7w → S2 12w → S3 4w → S2 46w → S3 4w → S2 50w → S3 5w → S2 25w current
Total tracked: 169 weeks across 10 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-04-21
3 appearances in last 60 days. First seen: 2024-04-16.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 25 · Vol 0.55x
2026-10-08S2
Wk 25 · Vol 0.55x
2026-10-07S2
Wk 24 · Vol 0.56x
2026-10-06S2
Wk 24 · Vol 0.82x
2026-10-05S2
Wk 24 · Vol 0.51x
2026-10-01S2
Wk 24 · Vol 0.55x
2026-09-30S2
Wk 24 · Vol 0.52x
2026-09-29S2
Wk 23 · Vol 0.92x
2026-09-28S2
Wk 23 · Vol 0.36x
2026-09-25S2
Wk 23 · Vol 0.55x
2026-09-24S2
Wk 23 · Vol 0.53x
2026-09-23S2
Wk 23 · Vol 0.52x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
SHILPAMED
wk 22 · -4.8% from hi
7.6
Moving averages & range
50 DMA
₹1,907.1
200 DMA
₹1,379.2
52W High
₹2,052.8
52W Low
₹853.1
5D Low
₹1,971.4
Resistance levels (recent highs)
20d High
₹2,052.8
60d High
₹2,052.8
120d High
₹2,052.8
250d High
₹2,052.8
Next resistance
+0.8%
to 20d High
Ask the Market AI about LAURUSLABSAsk →
P/E (TTM)
88.2
Forward 57.9
Earnings Growth (YoY)
+19.4%
Revenue +5.3%
ROE
+17.7%
Profit margin +13.0%
Dividend Yield
0.17%
P/B 14.1
About this companyHealth Care· Pharmaceuticals

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.